Athira Pharma, Inc. (NASDAQ:LONA) Given Average Rating of “Hold” by Brokerages

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $15.00.

A number of research firms recently weighed in on LONA. Wall Street Zen upgraded shares of Athira Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Piper Sandler initiated coverage on Athira Pharma in a research report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a research report on Monday, May 11th.

Institutional Trading of Athira Pharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC increased its holdings in shares of Athira Pharma by 244.1% in the fourth quarter. Perceptive Advisors LLC now owns 1,859,322 shares of the company’s stock worth $14,075,000 after purchasing an additional 1,319,026 shares during the period. Commodore Capital LP bought a new stake in Athira Pharma during the fourth quarter valued at $3,515,000. ADAR1 Capital Management LLC purchased a new position in Athira Pharma during the fourth quarter worth about $2,891,000. Spruce Street Capital LP purchased a new position in Athira Pharma during the fourth quarter worth about $2,980,000. Finally, Millennium Management LLC purchased a new position in Athira Pharma during the fourth quarter worth about $2,456,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Price Performance

Shares of NASDAQ:LONA opened at $7.57 on Thursday. The company has a market capitalization of $71.08 million, a price-to-earnings ratio of -1.45 and a beta of 2.01. Athira Pharma has a twelve month low of $3.24 and a twelve month high of $14.21. The stock’s 50-day simple moving average is $8.94.

Athira Pharma (NASDAQ:LONA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.73) earnings per share (EPS) for the quarter. Sell-side analysts expect that Athira Pharma will post -3.12 EPS for the current year.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.